FDA OKs hot-flash drug from Pfizer, Ligand

10/4/2013 | Bloomberg

The FDA has granted Pfizer and Ligand Pharmaceuticals approval for their osteoporosis and hot-flash treatment Duavee. The medication is to be used in postmenopausal women who haven't had a hysterectomy and who suffer moderate to severe hot flashes. The drug is also indicated for prevention of post-menopausal osteoporosis.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT